Structure Therapeutics (NASDAQ:GPCR – Get Free Report) had its target price decreased by equities researchers at JMP Securities from $91.00 to $86.00 in a research note issued on Friday, Benzinga reports. The firm currently has a “market outperform” rating on the stock. JMP Securities’ target price points to a potential upside of 154.66% from the company’s current price.
Other analysts also recently issued reports about the company. JPMorgan Chase & Co. started coverage on Structure Therapeutics in a report on Tuesday, May 21st. They issued an “overweight” rating and a $65.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, July 1st. Finally, BMO Capital Markets lifted their price objective on Structure Therapeutics from $83.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, June 7th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $84.63.
Check Out Our Latest Analysis on Structure Therapeutics
Structure Therapeutics Trading Down 2.1 %
Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last issued its earnings results on Thursday, May 9th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. On average, research analysts forecast that Structure Therapeutics will post -0.94 earnings per share for the current year.
Hedge Funds Weigh In On Structure Therapeutics
Large investors have recently added to or reduced their stakes in the company. Sectoral Asset Management Inc. bought a new position in Structure Therapeutics in the fourth quarter worth about $139,000. ADAR1 Capital Management LLC bought a new position in Structure Therapeutics in the fourth quarter worth about $163,000. Mather Group LLC. bought a new position in Structure Therapeutics in the second quarter worth about $214,000. Raymond James & Associates bought a new position in Structure Therapeutics in the fourth quarter worth about $233,000. Finally, Gilbert & Cook Inc. bought a new position in Structure Therapeutics in the second quarter worth about $229,000. 91.78% of the stock is currently owned by institutional investors.
Structure Therapeutics Company Profile
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Featured Stories
- Five stocks we like better than Structure Therapeutics
- The How And Why of Investing in Oil Stocks
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- Investing in Construction Stocks
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.